Astellas Pharma’s Post

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

Please check PALADIN Consortium Playbook & Resources Repository. It is a fantastic source of information to optimize collaborations between patient advocacy groups and biopharma companies! 👍 👍 👍 #patientadvocacy #patientcentricity #sanofi #sanofistories

Excited to share!!! The PALADIN-Consortium has launched its first set of resources, available free of charge, to organizations collaborating on medicines development. It has been an astonishing first year where in a short time, two dozen organizations representing biopharma and patient advocacy, came together to co- create the consortium, identified what was needed to support more efficient US focused collaborations and produced this initial set of foundational deliverables. This launch is just the start of great things we plan to deliver with the aim to transform the pace of medicines development. There are a plethora of excellent frameworks, educational platforms, and other resources available in the public domain, however, it is a challenge to understand what exists and easily find where the information is located. The central repository of resources serves as a consolidation of helpful links to the great work performed by various entities. Thank you to the organizations who have agreed to have their information posted. PALADIN is honored to be able to help bring visibility to your work. Others are welcomed to reach out and have their work shared in this forum. Teams can also stuggle to understand how to initiate a collaboration and that can lead to inaction or delays. The co-created frequently asked questions and playbook can serve as a support to any organization looking for quick answers related to ‘how to’. Understanding best practices related to clinical trial participation, and diversity & inclusion, are essential to transforming the pace of medicines development and the Consortium workstreams have gathered more than 100 sources that can be leveraged. Consolidation and transparency can reduce the probability of time being spent ‘reinventing the wheel’ and enable prioritization of solutions that work! These initial foundational resources hope to put time, and resources, back where it can be used on high impact actions and play a role in transforming the pace of medicines development. We are just scratching the surface and are excited for Year 2! #paladinconsortium #patientcentricity #sanofistories Tufts Center for the Study of Drug Development Lisa La Luna Susan G Koman Foundation Accelerated Cure Project for Multiple Sclerosis Aimed Alliance Allergy & Asthma Network American Kidney FundAstellas Pharma US AstraZeneca Black Health Matters Bristol Myers Squibb Cancer Support Community COPD Foundation CSL Daiichi Sankyo, Inc. Merck The Michael J. Fox Foundation for Parkinson's Research National Alliance for Caregiving National Bleeding Disorders Foundation Novo Nordisk Pediatric Dermatology Research Alliance - PeDRA Pfizer Sanofi Takeda Tigerlily Foundation Opus Genetics BioNTech SE

Strategic and meaningful engagement with patients and the patient advocacy groups (PAG) who are experts on the impact of disease on quality of life is essential for biopharmaceutical companies seeking to address the unmet needs of the patients they intend to treat. The PALADIN Consortium was created to maximize the impact of patient focused collaborations and #patientfocuseddrugdevelopment. To learn how PAGs and Sponsors of research are optimizing their collaborations please consider accessing the PALADIN Playbook and Resource Repository. Both the Playbook and the Resource Repository are accessible on https://bit.ly/3Im6uoG and are available for free. The Playbook provides process maps and forms to initiate and guide collaborations as well as template service and confidentiality agreements to expedite PAG-industry engagements. The Resource Repository contains over 100 identified and assessed best-in-class operational resources with links to the organizations that developed them. #patientadvocacy